Trial Search Results

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing hearing loss.

PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: sodium thiosulfate
  • Procedure: examination

Phase:

Phase 3

Eligibility


DISEASE CHARACTERISTICS:

   - Newly diagnosed (previously untreated or currently receiving cancer treatment for the
   diagnosis that made the patient eligible for this study) with germ cell tumor,
   hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy

   - Planning to receive a chemotherapy treatment regimen that includes a cumulative
   cisplatin dose ≥ 200 mg/m² with individual cisplatin doses to be infused over ≤ 6
   hours

   - Enrolled on hearing assessment clinical trial COG-ACCL05C1

      - Normal auditory results

PATIENT CHARACTERISTICS:

   - Karnofsky performance status (PS) 50-100% (for patients > 16 years of age)

   - Lansky PS 50-100% (for patients ≤ 16 years of age)

   - Serum sodium normal

   - Absolute granulocyte count > 1,000/mm³

   - Platelet count > 100,000/mm³

   - Creatinine clearance or radioisotope glomerular filtration rate ≥ 70mL/min OR serum
   creatinine between 0.4 and 1.7 mg/dL, based on age and gender

   - Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age

   - AST or ALT < 2.5 times ULN for age

   - Not pregnant or nursing

   - Negative pregnancy test (if patient has child-bearing capacity)

   - Fertile patients must use effective contraception

   - No known hypersensitivity to sodium thiosulfate or other thiol agents (e.g.,
   amifostine trihydrate, N-acetylcysteine, MESNA, or captopril)

PRIOR CONCURRENT THERAPY:

   - See Disease Characteristics

   - No prior platinum-based chemotherapy (cisplatin or carboplatin)

      - Other prior chemotherapy allowed

   - Prior cranial radiotherapy (e.g., for treatment of medulloblastoma) allowed provided
   normal hearing is documented after completion of radiotherapy and before enrollment
   and administration of cisplatin chemotherapy

   - At least 6 months since prior hematopoietic stem cell transplantation.

      - No evidence of graft-versus-host disease

   - No concurrent enrollment on another COG clinical trial for treatment of the cancer.

      - Concurrent enrollment on a non-COG clinical trial (e.g., Head start) allowed.

   - Cranial irradiation after the completion of all systemic chemotherapy allowed provided
   post end-of-treatment audiometry is completed prior to beginning irradiation.

   - Concurrent radiotherapy to extracranial sites allowed.

Ages Eligible for Study

1 Year - 18 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting